The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders

By  

Current Drug Targets, Vol. 8, Iss. 2, 2007-02 ,pp. : 247-256

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

BCR-ABL as a target for novel therapeutic interventions

By Kindler T   Meyer RG   Fischer T  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 1, 2002-02 ,pp. : 85-101

Informa Healthcare

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite

Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia - is it all BCR-ABL?

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 3-19

Bentham Science Publishers

Access to resources Recommend Favorite